Ibrutinib in combination with nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma: results from the phase 3 RESOLVE study

被引：0

作者：

Tempero, M. ^{[1
]}

Oh, D. ^{[2
]}

Macarulla, T. ^{[3
,4
]}

Reni, M. ^{[5
]}

Van Cutsem, E. ^{[6
,7
]}

Hendifar, A. ^{[8
]}

Waldschmidt, D. ^{[9
]}

Starling, N. ^{[10
]}

Bachet, J. ^{[11
]}

Chang, H. ^{[12
]}

Maurel, J. ^{[13
]}

Lonardi, S. ^{[14
]}

Coussens, L. ^{[15
]}

Fong, L. ^{[1
]}

Tsao, L. ^{[16
]}

Cole, G., Jr. ^{[16
]}

James, D. ^{[16
]}

Tebernero, J. ^{[3
,4
]}

机构：

[1] Univ Calif San Francisco, San Francisco, CA 94143 USA

[2] Seoul Natl Univ Hosp, Seoul, South Korea

[3] Vall dHebron Univ Hosp, Barcelona, Spain

[4] Inst Oncol VHIO, Barcelona, Spain

[5] IRCCS Osped, San Raffaele Sci Inst, Milan, Italy

[6] Univ Hosp Gasthuisberg, Leuven, Belgium

[7] Katholieke Univ Leuven, Leuven, Belgium

[8] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA

[9] Univ Cologne, Cologne, Germany

[10] Royal Marsden, London, England

[11] Sorbonne Univ, Paris, France

[12] Univ Ulsan, Coll Med, Seoul, South Korea

[13] Hosp Clin Barcelona, Barcelona, Spain

[14] Veneto Oncol Inst, Padua, Italy

[15] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA

[16] Pharmacyclics LLC, Sunnyvale, CA USA

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

O - 002

引用

页码：126 / 126

页数：1

共 50 条

[1] Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study
Tempero, M.
Oh, D-Y
Tabernero, J.
Reni, M.
Van Cutsem, E.
Hendifar, A.
Waldschmidt, D-T
Starling, N.
Bachet, J-B
Chang, H-M
Maurel, J.
Garcia-Carbonero, R.
Lonardi, S.
Coussens, L. M.
Fong, L.
Tsao, L. C.
Cole, G., Jr.
James, D.
Macarulla, T.
[J]. ANNALS OF ONCOLOGY, 2021, 32 (05) : 600 - 608
[2] Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma
P. G. Corrie
W. Qian
B. Basu
J. W. Valle
S. Falk
C. lwuji
H. Wasan
D. Palmer
M. Scott-Brown
J. Wadsley
S. Arif
J. Bridgewater
D. Propper
R. Gillmore
A. Gopinathan
R. Skells
P. Bundi
R. Brais
K. Dalchau
L. Bax
A. Chhabra
A. Machin
A. Dayim
K. McAdam
S. Cummins
L. Wall
R. Ellis
A. Anthoney
J. Evans
Y. T. Ma
C. Isherwood
A. Neesse
D. Tuveson
D. I. Jodrell
[J]. British Journal of Cancer, 2020, 122 : 1760 - 1768
[3] Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma
Corrie, P. G.
Qian, W.
Basu, B.
Valle, J. W.
Falk, S.
Iwuji, C.
Wasan, H.
Palmer, D.
Scott-Brown, M.
Wadsley, J.
Arif, S.
Bridgewater, J.
Propper, D.
Gillmore, R.
Gopinathan, A.
Skells, R.
Bundi, P.
Brais, R.
Dalchau, K.
Bax, L.
Chhabra, A.
Machin, A.
Dayim, A.
McAdam, K.
Cummins, S.
Wall, L.
Ellis, R.
Anthoney, A.
Evans, J.
Ma, Y. T.
Isherwood, C.
Neesse, A.
Tuveson, D.
Jodrell, D., I
[J]. BRITISH JOURNAL OF CANCER, 2020, 122 (12) : 1760 - 1768
[4] Efficacy of SBP-101, in combination with gemcitabine and nab-paclitaxel, in first-line treatment of metastatic pancreatic ductal adenocarcinoma
Kotasek, Dusan
Nagrial, Adnan
Lumba, Sumit
Tebbutt, Niall C.
George, Thomas J.
Smith, Sheri Lynn
Gagnon, Suzanne
Cullen, Michael T.
Walker, Michael J.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[5] A phase Ib study evaluating olaratumab in combination with nab-paclitaxel and gemcitabine in first-line treatment of metastatic pancreatic cancer.
Pelzer, Uwe
Bendell, Johanna C.
Womack, Mark S.
Bahary, Nathan
Macarulla, Teresa
Borazanci, Erkut Hasan
Levy, Donna Elise
Mo, Gary
Ramage, Samuel Cowan
Garrido-Laguna, Ignacio
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
[6] A randomized, double-blind, placebo-controlled study of ibrutinib, a Bruton tyrosine kinase inhibitor, with nab-paclitaxel and gemcitabine in the first-line treatment of patients with metastatic pancreatic adenocarcinoma (RESOLVE).
Tempero, Margaret A.
Coussens, Lisa M.
Fong, Lawrence
Manges, Robert
Singh, Priyanka
Li, Yunfeng
Cole, George W.
James, Danelle Frances
Tabernero, Josep
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[7] First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma
Pat Gulhati
Laura Prakash
Matthew H. G. Katz
Xuemei Wang
Milind Javle
Rachna Shroff
David Fogelman
Jeffrey E. Lee
Ching-Wei D. Tzeng
Jeffrey H. Lee
Brian Weston
Eric Tamm
Priya Bhosale
Eugene J. Koay
Anirban Maitra
Huamin Wang
Robert A. Wolff
Gauri R. Varadhachary
[J]. Annals of Surgical Oncology, 2019, 26 : 619 - 627
[8] First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma
Gulhati, Pat
Prakash, Laura
Katz, Matthew H. G.
Wang, Xuemei
Javle, Milind
Shroff, Rachna
Fogelman, David
Lee, Jeffrey E.
Tzeng, Ching-Wei D.
Lee, Jeffrey H.
Weston, Brian
Tamm, Eric
Bhosale, Priya
Koay, Eugene J.
Maitra, Anirban
Wang, Huamin
Wolff, Robert A.
Varadhachary, Gauri R.
[J]. ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (02) : 619 - 627
[9] A randomized, multicenter, double-blind, placebo-controlled study of the Bruton tyrosine kinase inhibitor, ibrutinib, versus placebo in combination with nab-paclitaxel and gemcitabine in the first-line treatment of patients with metastatic pancreatic adenocarcinoma (RESOLVE).
Tempero, Margaret A.
Coussens, Lisa M.
Fong, Lawrence
Manges, Robert
Singh, Priyanka
Li, Yunfeng
Cole, George W.
James, Danelle Frances
Tabernero, Josep
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
[10] First-line Nab-paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer from Routine Clinical Practice
Vogel, Arndt
Pelzer, Uwe
Salah-Eddin, Al-Batran
Koester, Wolf
[J]. IN VIVO, 2014, 28 (06): : 1135 - 1140

← 1 2 3 4 5 →